Andrew BADROT, M.Sc. 

Andrew BADROT is the CEO of C2 PHARMA, a manufacturer and distributor of Active Pharmaceutical Ingredients (APIs) globally. The company was founded in 2014 and is headquartered in Luxembourg, combining the strengths of its heritage from Brazil’s Centroflora and Switzerland’s CMS Pharma.


– CEO of CMS-Pharma, a provider of M&A advisory services and business strategy consulting to pharmaceutical CMOs.
– Vice President of Strategy, Exclusive Synthesis sector; Lonza AG. Basel, Switzerland (2007-2010)
-Project leader in Corporate Strategy; Schott AG. Mainz, Germany (2005-2007)
– Senior Manager, Business Development and Strategy; Sun Microsystems. Menlo Park, California, USA (2001-2004)
– Business Development; Palo Alto, California, USA (2000-2001)
– Nuclear Engineer; Schlumberger.Houston, Texas, USA (1998)


Andrew holds an MS in Engineering Economics Systems and Operations Research from Stanford University, California, USA and an Engineering Degree in Nuclear Physics from the Institut Polytechnique in Grenoble, France.